The rho kinases: Critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis

Pharmacological Reviews

Volumn 67, Issue 1, 2015, Pages 103-117

  Knipe, Rachel S ^a   Tager, Andrew M ^a   Liao, James K ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE INHIBITOR; RHO KINASE;

ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DISEASE MODEL; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; HUMAN; IDIOPATHIC PULMONARY FIBROSIS; LUNG; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG DESIGN; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MOLECULAR TARGETED THERAPY; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84916241169     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.114.009381     Document Type: Article

References (148)

1. Abraham DJ, Eckes B, Rajkumar V, and Krieg T (2007) New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma. Curr Rheumatol Rep 9:136–143.
2. Ahluwalia N, Shea BS, and Tager AM (2014) New therapeutic targets in idiopathic pulmonary fibrosis: aiming to rein in runaway wound healing responses. Am J Respir Crit Care Med 190:867–878.
3. Akhmetshina A, Dees C, Pileckyte M, Szucs G, Spriewald BM, Zwerina J, Distler O, Schett G, and Distler JH (2008) Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis Rheum 58:2553–2564.
4. Amano M, Ito M, Kimura K, Fukata Y, Chihara K, Nakano T, Matsuura Y, and Kaibuchi K (1996) Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). J Biol Chem 271:20246–20249.
5. Annes JP, Munger JS, and Rifkin DB (2003) Making sense of latent TGFbeta activation. J Cell Sci 116:217–224.
6. Balestrini JL, Chaudhry S, Sarrazy V, Koehler A, and Hinz B (2012) The mechanical memory of lung myofibroblasts. Integr Biol (Camb) 4:410–421.
7. Bei Y, Hua-Huy T, Duong-Quy S, Nguyen VH, Chen W, Nicco C, Batteux F, and Dinh-Xuan AT (2013) Long-term treatment with fasudil improves bleomycininduced pulmonary fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation. Pulm Pharmacol Ther 26:635–643.
8. Blackwell TS, Tager AM, Borok Z, Moore BB, Schwartz DA, Anstrom KJ, Bar-Joseph Z, Bitterman P, Blackburn MR, and Bradford W, et al. (2014) Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report. Am J Respir Crit Care Med 189:214–222.
9. Bonniaud P, Margetts PJ, Kolb M, Schroeder JA, Kapoun AM, Damm D, Murphy A, Chakravarty S, Dugar S, and Higgins L, et al. (2005) Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am J Respir Crit Care Med 171:889–898.
10. Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, Chaudhry SI, Harrington K, Williamson P, Moeendarbary E, and Charras G, et al. (2013) Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol 15:637–646.
11. Carbajal JM, Gratrix ML, Yu CH, and Schaeffer RC Jr (2000) ROCK mediates thrombin’s endothelial barrier dysfunction. Am J Physiol Cell Physiol 279: C195–C204.
12. Chevrier V, Piel M, Collomb N, Saoudi Y, Frank R, Paintrand M, Narumiya S, Bornens M, and Job D (2002) The Rho-associated protein kinase p160ROCK is required for centrosome positioning. J Cell Biol 157:807–817.
13. Coleman ML, Sahai EA, Yeo M, Bosch M, Dewar A, and Olson MF (2001) Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. Nat Cell Biol 3:339–345.
14. Coward WR, Saini G, and Jenkins G (2010) The pathogenesis of idiopathic pulmonary fibrosis. Ther Adv Respir Dis 4:367–388.
15. Davies SP, Reddy H, Caivano M, and Cohen P (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351:95–105.
16. Desmoulière A, Chaponnier C, and Gabbiani G (2005) Tissue repair, contraction, and the myofibroblast. Wound Repair Regen 13:7–12.
17. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, Anders RA, Maitra A, and Pan D (2007) Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 130:1120–1133.
18. Duffield JS, Lupher M, Thannickal VJ, and Wynn TA (2013) Host responses in tissue repair and fibrosis. Annu Rev Pathol 8:241–276.
19. Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M, and Bicciato S, et al. (2011) Role of YAP/TAZ in mechanotransduction. Nature 474:179–183.
20. Dvorak HF (1986) Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315:1650–1659.
21. Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen T, Ginsburg D, and Simon RH (1996) Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 97: 232–237.
22. Eto M, Senba S, Morita F, and Yazawa M (1997) Molecular cloning of a novel phosphorylation-dependent inhibitory protein of protein phosphatase-1 (CPI17) in smooth muscle: its specific localization in smooth muscle. FEBS Lett 410:356–360.
23. Farkas L, Gauldie J, Voelkel NF, and Kolb M (2011) Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factors. Am J Respir Cell Mol Biol 45:1–15.
24. Fattman CL (2008) Apoptosis in pulmonary fibrosis: too much or not enough? Antioxid Redox Signal 10:379–385.
25. Feng J, Ito M, Ichikawa K, Isaka N, Nishikawa M, Hartshorne DJ, and Nakano T (1999) Inhibitory phosphorylation site for Rho-associated kinase on smooth muscle myosin phosphatase. J Biol Chem 274:37385–37390.
26. Frisch SM and Francis H (1994) Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124:619–626.
27. Fu P, Liu F, Su S, Wang W, Huang XR, Entman ML, Schwartz RJ, Wei L, and Lan HY (2006) Signaling mechanism of renal fibrosis in unilateral ureteral obstructive kidney disease in ROCK1 knockout mice. J Am Soc Nephrol 17:3105–3114.
28. Funke M, Zhao Z, Xu Y, Chun J, and Tager AM (2012) The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury. Am J Respir Cell Mol Biol 46:355–364.
29. Gauthaman K, Fong CY, and Bongso A (2010) Effect of ROCK inhibitor Y-27632 on normal and variant human embryonic stem cells (hESCs) in vitro: its benefits in hESC expansion. Stem Cell Rev 6:86–95.
30. Georges PC, Hui JJ, Gombos Z, McCormick ME, Wang AY, Uemura M, Mick R, Janmey PA, Furth EE, and Wells RG (2007) Increased stiffness of the rat liver precedes matrix deposition: implications for fibrosis. Am J Physiol Gastrointest Liver Physiol 293:G1147–G1154.
31. Giri SN, Hyde DM, and Hollinger MA (1993) Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorax 48:959–966.
32. Gross TJ and Hunninghake GW (2001) Idiopathic pulmonary fibrosis. N Engl J Med 345:517–525.
33. Günther A, Lübke N, Ermert M, Schermuly RT, Weissmann N, Breithecker A, Markart P, Ruppert C, Quanz K, and Ermert L, et al. (2003) Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Crit Care Med 168:1358–1365.
34. Hamaguchi T, Ito M, Feng J, Seko T, Koyama M, Machida H, Takase K, Amano M, Kaibuchi K, and Hartshorne DJ, et al. (2000) Phosphorylation of CPI-17, an inhibitor of myosin phosphatase, by protein kinase N. Biochem Biophys Res Commun 274:825–830.
35. Hao Y, Chun A, Cheung K, Rashidi B, and Yang X (2008) Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem 283:5496–5509.
36. Horan GS, Wood S, Ona V, Li DJ, Lukashev ME, Weinreb PH, Simon KJ, Hahm K, Allaire NE, and Rinaldi NJ, et al. (2008) Partial inhibition of integrin alpha(v) beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med 177:56–65.
37. Horani A, Nath A, Wasserman MG, Huang T, and Brody SL (2013) Rho-associated protein kinase inhibition enhances airway epithelial Basal-cell proliferation and lentivirus transduction. Am J Respir Cell Mol Biol 49:341–347.
38. Howell DC, Johns RH, Lasky JA, Shan B, Scotton CJ, Laurent GJ, and Chambers RC (2005) Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis. Am J Pathol 166:1353–1365.
39. Huang LS, Fu P, Patel P, Harijith A, Sun T, Zhao Y, Garcia JG, Chun J, and Natarajan V (2013) Lysophosphatidic acid receptor-2 deficiency confers protection against bleomycin-induced lung injury and fibrosis in mice. Am J Respir Cell Mol Biol 49:912–922.
40. Huang X, Yang N, Fiore VF, Barker TH, Sun Y, Morris SW, Ding Q, Thannickal VJ, and Zhou Y (2012) Matrix stiffness-induced myofibroblast differentiation is mediated by intrinsic mechanotransduction. Am J Respir Cell Mol Biol 47:340–348.
41. Hunninghake GW and Schwarz MI (2007) Does current knowledge explain the pathogenesis of idiopathic pulmonary fibrosis? A perspective. Proc Am Thorac Soc 4:449–452.
42. Ikenoya M, Hidaka H, Hosoya T, Suzuki M, Yamamoto N, and Sasaki Y (2002) Inhibition of rho-kinase-induced myristoylated alanine-rich C kinase substrate (MARCKS) phosphorylation in human neuronal cells by H-1152, a novel and specific Rho-kinase inhibitor. J Neurochem 81:9–16.
43. Imokawa S, Sato A, Hayakawa H, Kotani M, Urano T, and Takada A (1997) Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Am J Respir Crit Care Med 156: 631–636.
44. Ishimaru K, Ueno H, Kagitani S, Takabayashi D, Takata M, and Inoue H (2007) Fasudil attenuates myocardial fibrosis in association with inhibition of monocyte/macrophage infiltration in the heart of DOCA/salt hypertensive rats. J Cardiovasc Pharmacol 50:187–194.
45. Ishizaki T, Maekawa M, Fujisawa K, Okawa K, Iwamatsu A, Fujita A, Watanabe N, Saito Y, Kakizuka A, and Morii N, et al. (1996) The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. EMBO J 15:1885–1893.
46. Ishizaki T, UehataM, Tamechika I, Keel J, Nonomura K,MaekawaM, and Narumiya S (2000) Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol 57:976–983.
47. Iwasaki A and Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5:987–995.
48. Jenkins RG, Su X, Su G, Scotton CJ, Camerer E, Laurent GJ, Davis GE, Chambers RC, Matthay MA, and Sheppard D (2006) Ligation of protease-activated receptor 1 enhances alpha(v)beta6 integrin-dependent TGF-beta activation and promotes acute lung injury. J Clin Invest 116:1606–1614.
49. Jiang C, Huang H, Liu J, Wang Y, Lu Z, and Xu Z (2012) Fasudil, a rho-kinase inhibitor, attenuates bleomycin-induced pulmonary fibrosis in mice. Int J Mol Sci 13:8293–8307.
50. Kaczorowski DJ, Mollen KP, Edmonds R, and Billiar TR (2008) Early events in the recognition of danger signals after tissue injury. J Leukoc Biol 83:546–552.
51. Kawano Y, Fukata Y, Oshiro N, Amano M, Nakamura T, Ito M, Matsumura F, Inagaki M, and Kaibuchi K (1999) Phosphorylation of myosin-binding subunit (MBS) of myosin phosphatase by Rho-kinase in vivo. J Cell Biol 147:1023–1038.
52. Kenyon NJ, Ward RW, McGrew G, and Last JA (2003) TGF-beta1 causes airway fibrosis and increased collagen I and III mRNA in mice. Thorax 58:772–777.
53. Kikuchi Y, Yamada M, Imakiire T, Kushiyama T, Higashi K, Hyodo N, Yamamoto K, Oda T, Suzuki S, and Miura S (2007) A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J Endocrinol 192:595–603.
54. Kitamura K, Tada S, Nakamoto N, Toda K, Horikawa H, Kurita S, Tsunematsu S, Kumagai N, Ishii H, and Saito H, et al. (2007) Rho/Rho kinase is a key enzyme system involved in the angiotensin II signaling pathway of liver fibrosis and steatosis. J Gastroenterol Hepatol 22:2022–2033.
55. Kitazawa T, Takizawa N, Ikebe M, and Eto M (1999) Reconstitution of protein kinase C-induced contractile Ca2+ sensitization in triton X-100-demembranated rabbit arterial smooth muscle. J Physiol 520:139–152.
56. Komers R, Oyama TT, Beard DR, Tikellis C, Xu B, Lotspeich DF, and Anderson S (2011) Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure. Kidney Int 79:432–442.
57. Koyama M, Ito M, Feng J, Seko T, Shiraki K, Takase K, Hartshorne DJ, and Nakano T (2000) Phosphorylation of CPI-17, an inhibitory phosphoprotein of smooth muscle myosin phosphatase, by Rho-kinase. FEBS Lett 475:197–200.
58. Koyanagi M, Takahashi J, Arakawa Y, Doi D, Fukuda H, Hayashi H, Narumiya S, and Hashimoto N (2008) Inhibition of the Rho/ROCK pathway reduces apoptosis during transplantation of embryonic stem cell-derived neural precursors. J Neurosci Res 86:270–280.
59. Kuwano K, Kunitake R, Kawasaki M, Nomoto Y, Hagimoto N, Nakanishi Y, and Hara N (1996) P21Waf1/Cip1/Sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 154:477–483.
60. Lech M and Anders HJ (2013) Macrophages and fibrosis: How resident and infiltrating mononuclear phagocytes orchestrate all phases of tissue injury and repair. Biochim Biophys Acta 1832:989–997.
61. Leung T, Manser E, Tan L, and Lim L (1995) A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J Biol Chem 270:29051–29054.
62. Li X, Meng G, Krawetz R, Liu S, and Rancourt DE (2008) The ROCK inhibitor Y-27632 enhances the survival rate of human embryonic stem cells following cryopreservation. Stem Cells Dev 17:1079–1085.
63. Li Z, Dranoff JA, Chan EP, Uemura M, Sevigny J, and Wells RG (2007) Transforming growth factor-beta and substrate stiffness regulate portal fibroblast activation in culture. Hepatology 46:1246–1256.
64. Liao JK, Seto M, and Noma K (2007) Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol 50:17–24.
65. Lipson KE, Wong C, Teng Y, and Spong S (2012) CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair 5 (Suppl 1):S24.
66. Liu F, Mih JD, Shea BS, Kho AT, Sharif AS, Tager AM, and Tschumperlin DJ (2010) Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression. J Cell Biol 190:693–706.
67. Liu GJ, Wang ZJ, Wang YF, Xu LL, Wang XL, Liu Y, Luo GJ, He GH, and Zeng YJ (2012) Systematic assessment and meta-analysis of the efficacy and safety of fasudil in the treatment of cerebral vasospasm in patients with subarachnoid hemorrhage. Eur J Clin Pharmacol 68:131–139.
68. Maekawa M, Ishizaki T, Boku S, Watanabe N, Fujita A, Iwamatsu A, Obinata T, Ohashi K, Mizuno K, and Narumiya S (1999) Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science 285:895–898.
69. Matsui T, Maeda M, Doi Y, Yonemura S, Amano M, Kaibuchi K, Tsukita S, and Tsukita S (1998) Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association. J Cell Biol 140:647–657.
70. McKeown S, Richter AG, O’Kane C, McAuley DF, and Thickett DR (2009) MMP expression and abnormal lung permeability are important determinants of outcome in IPF. Eur Respir J 33:77–84.
71. Mogulkoc N, Brutsche MH, Bishop PW, Murby B, Greaves MS, Horrocks AW, Wilson M, McCullough C, Prescott M, and Egan JJ; Greater Manchester Pulmonary Fibrosis Consortium (2001) Pulmonary (99m)Tc-DTPA aerosol clearance and survival in usual interstitial pneumonia (UIP). Thorax 56:916–923.
72. Moodley YP, Caterina P, Scaffidi AK, Misso NL, Papadimitriou JM, McAnulty RJ, Laurent GJ, Thompson PJ, and Knight DA (2004) Comparison of the morphological and biochemical changes in normal human lung fibroblasts and fibroblasts derived from lungs of patients with idiopathic pulmonary fibrosis during FasL-induced apoptosis. J Pathol 202:486–495.
73. Moore BB, Lawson WE, Oury TD, Sisson TH, Raghavendran K, and Hogaboam CM (2013) Animal models of fibrotic lung disease. Am J Respir Cell Mol Biol 49:167–179.
74. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, McMurtry IF, Stenmark KR, Thistlethwaite PA, and Weissmann N, et al. (2009) Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 54(1, Suppl) S20–S31.
75. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, and Matthay MA, et al. (1999) The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96:319–328.
76. Murray PJ and Wynn TA (2011) Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 11:723–737.
77. Nagatoya K, Moriyama T, Kawada N, Takeji M, Oseto S, Murozono T, Ando A, Imai E, and Hori M (2002) Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int 61:1684–1695.
78. Nakagawa O, Fujisawa K, Ishizaki T, Saito Y, Nakao K, and Narumiya S (1996) ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett 392:189–193.
79. Navaratnam V, Fogarty AW, McKeever T, Thompson N, Jenkins G, Johnson SR, Dolan G, Kumaran M, Pointon K, and Hubbard RB (2014) Presence of a prothrombotic state in people with idiopathic pulmonary fibrosis: a population-based case-control study. Thorax 69:207–215.
80. Niiro N, Koga Y, and Ikebe M (2003) Agonist-induced changes in the phosphorylation of the myosin- binding subunit of myosin light chain phosphatase and CPI17, two regulatory factors of myosin light chain phosphatase, in smooth muscle. Biochem J 369:117–128.
81. Nohria A, Prsic A, Liu PY, Okamoto R, Creager MA, Selwyn A, Liao JK, and Ganz P (2009) Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis 205:517–521.
82. Noma K, Oyama N, and Liao JK (2006) Physiological role of ROCKs in the cardiovascular system. Am J Physiol Cell Physiol 290:C661–C668.
83. Ohashi K, Nagata K, Maekawa M, Ishizaki T, Narumiya S, and Mizuno K (2000) Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at threonine 508 within the activation loop. J Biol Chem 275:3577–3582.
84. Olman MA, Mackman N, Gladson CL, Moser KM, and Loskutoff DJ (1995) Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse. J Clin Invest 96:1621–1630.
85. Olman MA, Simmons WL, Pollman DJ, Loftis AY, Bini A, Miller EJ, Fuller GM, and Rivera KE (1996) Polymerization of fibrinogen in murine bleomycin-induced lung injury. Am J Physiol 271:L519–L526.
86. Olson EN and Nordheim A (2010) Linking actin dynamics and gene transcription to drive cellular motile functions. Nat Rev Mol Cell Biol 11:353–365.
87. Peng W, Zhou Q, Ao X, Tang R, and Xiao Z (2013) Inhibition of Rho-kinase alleviates peritoneal fibrosis and angiogenesis in a rat model of peritoneal dialysis. Ren Fail 35:958–966.
88. Plataki M, Koutsopoulos AV, Darivianaki K, Delides G, Siafakas NM, and Bouros D (2005) Expression of apoptotic and antiapoptotic markers in epithelial cells in idiopathic pulmonary fibrosis. Chest 127:266–274.
89. Poosti F, Yazdani S, Dolman ME, Kok RJ, Chen C, Ding G, Lacombe M, Prakash J, van den Born J, and Hillebrands JL, et al. (2012) Targeted inhibition of renal Rho kinase reduces macrophage infiltration and lymphangiogenesis in acute renal allograft rejection. Eur J Pharmacol 694:111–119.
90. Puthawala K, Hadjiangelis N, Jacoby SC, Bayongan E, Zhao Z, Yang Z, Devitt ML, Horan GS, Weinreb PH, and Lukashev ME, et al. (2008) Inhibition of integrin alpha(v)beta6, an activator of latent transforming growth factor-beta, prevents radiation-induced lung fibrosis. Am J Respir Crit Care Med 177:82–90.
91. Raghu G, Anstrom KJ, King TE Jr, Lasky JA, and Martinez FJ Idiopathic Pulmonary Fibrosis Clinical Research Network (2012) Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 366:1968–1977.
92. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, and Lasky JA, et al.; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824.
93. Riento K and Ridley AJ (2003) Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol 4:446–456.
94. Rikitake Y, Kim HH, Huang Z, Seto M, Yano K, Asano T, Moskowitz MA, and Liao JK (2005a) Inhibition of Rho kinase (ROCK) leads to increased cerebral blood flow and stroke protection. Stroke 36:2251–2257.
95. Rikitake Y and Liao JK (2005) Rho GTPases, statins, and nitric oxide. Circ Res 97: 1232–1235.
96. Rikitake Y, Oyama N, Wang CY, Noma K, Satoh M, Kim HH, and Liao JK (2005b) Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1+/- haploinsufficient mice. Circulation 112:2959–2965.
97. Sakai N, Chun J, Duffield JS, Wada T, Luster AD, and Tager AM (2013) LPA1- induced cytoskeleton reorganization drives fibrosis through CTGF-dependent fibroblast proliferation. FASEB J 27:1830–1846
98. Sakai N and Tager AM (2013) Fibrosis of two: Epithelial cell-fibroblast interactions in pulmonary fibrosis. Biochim Biophys Acta 1832:911–921.
99. Sandbo N, Kregel S, Taurin S, Bhorade S, and Dulin NO (2009) Critical role of serum response factor in pulmonary myofibroblast differentiation induced by TGF-beta. Am J Respir Cell Mol Biol 41:332–338.
100. Sandbo N, Lau A, Kach J, Ngam C, Yau D, and Dulin NO (2011) Delayed stress fiber formation mediates pulmonary myofibroblast differentiation in response to TGF-b. Am J Physiol Lung Cell Mol Physiol 301:L656–L666.
101. Santibañez JF, Quintanilla M, and Bernabeu C (2011) TGF-b/TGF-b receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 121: 233–251.
102. Satoh S, Yamaguchi T, Hitomi A, Sato N, Shiraiwa K, Ikegaki I, Asano T, and Shimokawa H (2002) Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction. Eur J Pharmacol 455:169–174.
103. Scotton CJ and Chambers RC (2007) Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest 132:1311–1321.
104. Scotton CJ, Krupiczojc MA, Königshoff M, Mercer PF, Lee YC, Kaminski N, Morser J, Post JM, Maher TM, and Nicholson AG, et al. (2009) Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest 119:2550–2563.
105. Sebbagh M, Renvoizé C, Hamelin J, Riché N, Bertoglio J, and Bréard J (2001) Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing. Nat Cell Biol 3:346–352.
106. Selman M, King TE, and Pardo A; American Thoracic Society;; European Respiratory Society;; American College of Chest Physicians (2001) Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 134:136–151.
107. Selman M and Pardo A (2006) Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc 3:364–372.
108. Shen Q, Wu MH, and Yuan SY (2009) Endothelial contractile cytoskeleton and microvascular permeability. Cell Health Cytoskelet 2009:43–50.
109. Sheppard D (2006) Transforming growth factor beta: a central modulator of pulmonary and airway inflammation and fibrosis. Proc Am Thorac Soc 3:413–417.
110. Shi J, Zhang YW, Summers LJ, Dorn GW 2nd, and Wei L (2008) Disruption of ROCK1 gene attenuates cardiac dilation and improves contractile function in pathological cardiac hypertrophy. J Mol Cell Cardiol 44:551–560.
111. Shibuya M, Suzuki Y, Sugita K, Saito I, Sasaki T, Takakura K, Nagata I, Kikuchi H, Takemae T, and Hidaka H, et al. (1992) Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebocontrolled double-blind trial. J Neurosurg 76:571–577.
112. Shimizu Y, Dobashi K, Iizuka K, Horie T, Suzuki K, Tukagoshi H, Nakazawa T, Nakazato Y, and Mori M (2001) Contribution of small GTPase Rho and its target protein rock in a murine model of lung fibrosis. Am J Respir Crit Care Med 163: 210–217.
113. Shimizu Y, Thumkeo D, Keel J, Ishizaki T, Oshima H, OshimaM, Noda Y, Matsumura F, Taketo MM, and Narumiya S (2005) ROCK-I regulates closure of the eyelids and ventral body wall by inducing assembly of actomyosin bundles. J Cell Biol 168: 941–953.
114. Shimokawa H, Hiramori K, Iinuma H, Hosoda S, Kishida H, Osada H, Katagiri T, Yamauchi K, Yui Y, and Minamino T, et al. (2002) Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol 40:751–761.
115. Stefater JA 3rd, Ren S, Lang RA, and Duffield JS (2011) Metchnikoff’s policemen: macrophages in development, homeostasis and regeneration. Trends Mol Med 17: 743–752.
116. Sumi T, Matsumoto K, and Nakamura T (2001) Specific activation of LIM kinase 2 via phosphorylation of threonine 505 by ROCK, a Rho-dependent protein kinase. J Biol Chem 276:670–676.
117. Sun H, Breslin JW, Zhu J, Yuan SY, and Wu MH (2006) Rho and ROCK signaling in VEGF-induced microvascular endothelial hyperpermeability. Microcirculation 13: 237–247.
118. Suzuki Y, Shibuya M, Satoh S, Sugimoto Y, and Takakura K (2007) A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage. Surg Neurol 68:126–131; discussion 131–132.
119. Tada S, Iwamoto H, Nakamuta M, Sugimoto R, Enjoji M, Nakashima Y, and Nawata H (2001) A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamineinduced hepatic fibrosis in rats. J Hepatol 34:529–536.
120. Tager AM, LaCamera P, Shea BS, Campanella GS, Selman M, Zhao Z, Polosukhin V, Wain J, Karimi-Shah BA, and Kim ND, et al. (2008) The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 14:45–54.
121. Takemoto M, Sun J, Hiroki J, Shimokawa H, and Liao JK (2002) Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 106:57–62.
122. Tasaka S, Koh H, Yamada W, Shimizu M, Ogawa Y, Hasegawa N, Yamaguchi K, Ishii Y, Richer SE, and Doerschuk CM, et al. (2005) Attenuation of endotoxininduced acute lung injury by the Rho-associated kinase inhibitor, Y-27632. Am J Respir Cell Mol Biol 32:504–510.
123. Thannickal VJ and Horowitz JC (2006) Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc Am Thorac Soc 3:350–356.
124. Thomasy SM, Morgan JT, Wood JA, Murphy CJ, and Russell P (2013) Substratum stiffness and latrunculin B modulate the gene expression of the mechanotransducers YAP and TAZ in human trabecular meshwork cells. Exp Eye Res 113:66–73.
125. Thumkeo D, Keel J, Ishizaki T, Hirose M, Nonomura K, Oshima H, Oshima M, Taketo MM, and Narumiya S (2003) Targeted disruption of the mouse rhoassociated kinase 2 gene results in intrauterine growth retardation and fetal death. Mol Cell Biol 23:5043–5055.
126. Tschumperlin DJ, Liu F, and Tager AM (2013) Biomechanical regulation of mesenchymal cell function. Curr Opin Rheumatol 25:92–100.
127. van Nieuw Amerongen GP, van Delft S, Vermeer MA, Collard JG, and van Hinsbergh VW (2000a) Activation of RhoA by thrombin in endothelial hyperpermeability: role of Rho kinase and protein tyrosine kinases. Circ Res 87:335–340.
128. van Nieuw Amerongen GP, Vermeer MA, and van Hinsbergh VW (2000b) Role of RhoA and Rho kinase in lysophosphatidic acid-induced endothelial barrier dysfunction. Arterioscler Thromb Vasc Biol 20:E127–E133.
129. Velasco G, Armstrong C, Morrice N, Frame S, and Cohen P (2002) Phosphorylation of the regulatory subunit of smooth muscle protein phosphatase 1M at Thr850 induces its dissociation from myosin. FEBS Lett 527:101–104.
130. Vicari RM, Chaitman B, Keefe D, Smith WB, Chrysant SG, Tonkon MJ, Bittar N, Weiss RJ, Morales-Ballejo H, and Thadani U; Fasudil Study Group (2005) Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebocontrolled, phase 2 trial. J Am Coll Cardiol 46:1803–1811.
131. Wang HW, Liu PY, Oyama N, Rikitake Y, Kitamoto S, Gitlin J, Liao JK, and Boisvert WA (2008) Deficiency of ROCK1 in bone marrow-derived cells protects against atherosclerosis in LDLR-/- mice. FASEB J 22:3561–3570.
132. Wang Z, Wang DZ, Hockemeyer D, McAnally J, Nordheim A, and Olson EN (2004) Myocardin and ternary complex factors compete for SRF to control smooth muscle gene expression. Nature 428:185–189.
133. Washida N, Wakino S, Tonozuka Y, Homma K, Tokuyama H, Hara Y, Hasegawa K, Minakuchi H, Fujimura K, and Hosoya K, et al. (2011) Rho-kinase inhibition ameliorates peritoneal fibrosis and angiogenesis in a rat model of peritoneal sclerosis. Nephrol Dial Transplant 26:2770–2779.
134. Watanabe K, Ueno M, Kamiya D, Nishiyama A, Matsumura M, Wataya T, Takahashi JB, Nishikawa S, Nishikawa S, and Muguruma K, et al. (2007) A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat Biotechnol 25: 681–686.
135. Wilhelm KR, Roan E, Ghosh MC, Parthasarathi K, and Waters CM (2014) Hyperoxia increases the elastic modulus of alveolar epithelial cells through Rho kinase. FEBS J 281:957–969.
136. Wipff PJ, Rifkin DB, Meister JJ, and Hinz B (2007) Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J Cell Biol 179:1311–1323.
137. Wojciak-Stothard B and Ridley AJ (2002) Rho GTPases and the regulation of endothelial permeability. Vascul Pharmacol 39:187–199.
138. Woodsome TP, Eto M, Everett A, Brautigan DL, and Kitazawa T (2001) Expression of CPI-17 and myosin phosphatase correlates with Ca(2+) sensitivity of protein kinase C-induced contraction in rabbit smooth muscle. J Physiol 535:553–564.
139. Wu DJ, Xu JZ, Wu YJ, Jean-Charles L, Xiao B, Gao PJ, and Zhu DL (2009) Effects of fasudil on early atherosclerotic plaque formation and established lesion progression in apolipoprotein E-knockout mice. Atherosclerosis 207:68–73.
140. Wynn TA and Ramalingam TR (2012) Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 18:1028–1040.
141. Xu MY, Porte J, Knox AJ, Weinreb PH, Maher TM, Violette SM, McAnulty RJ, Sheppard D, and Jenkins G (2009) Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q). Am J Pathol 174:1264–1279.
142. Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH, Zhao J, Yuan H, Tumaneng K, and Li H, et al. (2012) Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 150:780–791.
143. Zhang YM, Bo J, Taffet GE, Chang J, Shi J, Reddy AK, Michael LH, Schneider MD, Entman ML, and Schwartz RJ, et al. (2006) Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis. FASEB J 20: 916–925.
144. Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, Xie J, Ikenoue T, Yu J, and Li L, et al. (2007) Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 21:2747–2761.
145. Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu J, Lin JD, Wang CY, and Chinnaiyan AM, et al. (2008) TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 22:1962–1971.
146. Zhao J, Zhou D, Guo J, Ren Z, Zhou L, Wang S, Zhang Y, Xu B, Zhao K, and Wang R, et al.; Fasudil Aneurysmal Subarachnoid Hemorrhage Study Group (2011) Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: final results of a randomized trial of fasudil versus nimodipine. Neurol Med Chir (Tokyo) 51: 679–683.
147. Zhou H, Fang C, Zhang L, Deng Y, Wang M, and Meng F (2014) Fasudil hydrochloride hydrate, a Rho-kinase inhibitor, ameliorates hepatic fibrosis in rats with type 2 diabetes. Chin Med J (Engl) 127:225–231.
148. Zhou Y, Huang X, Hecker L, Kurundkar D, Kurundkar A, Liu H, Jin TH, Desai L, Bernard K, and Thannickal VJ (2013) Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J Clin Invest 123: 1096–1108.